Noopur Bhatnagar

Dr. Noopur Bhatnagar

Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
JSJeeva Subbiah
Jeeva Subbiah
JOJudy Oh
Judy Oh
KKKi-Hye Kim
Ki-Hye Kim
CSChong Shin
Chong Shin
BPBo Ryoung Park
Bo Ryoung Park
SKSang-Moo Kang
Sang-Moo Kang
We developed a new chimeric M2e and H3 hemagglutinin (HA) stalk protein vaccine (M2e-H3 stalk) by genetic engineering of modified H3 stalk domain conjugated with conserved M2e epitopes to overcome the drawbacks of low efficacy by monomeric domain-based universal vaccines. M2e-H3 stalk protein expressed and purified from Escherichia coli was thermostable, displaying native-like antigenic epitopes recognized by antisera of different HA subtype proteins and influenza A virus infections. Adjuvanted M2e-H3 stalk vaccination induced M2e and stalk-specific IgG antibodies recognizing viral antigens on virus particles and on the infected cell surface, CD4+ and CD8+ T-cell responses, and antibody-dependent cytotoxic cell surrogate activity in mice. M2e-H3 stalk was found to confer protection against heterologous and heterosubtypic cross-group subtype viruses (H1N1, H5N1, H9N2, H3N2, H7N9) at similar levels in adult and aged mice. These results provide evidence that M2e-H3 stalk chimeric proteins can be developed as a universal influenza A virus vaccine candidate for young and aged populations.

16 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LWLewins Walter
Lewins Walter
APAdani Pujada
Adani Pujada
Noopur BhatnagarNoopur Bhatnagar
Noopur Bhatnagar
ABAgnieszka B Bialkowska
Agnieszka B Bialkowska
VYVincent W. Yang
Vincent W. Yang
PGPallavi Garg
Pallavi Garg
Epithelial derived-matrix metalloproteinase (MMP9) exhibits a novel defensive role of tumor suppressor in colitis associated cancer by activating MMP9-Notch1-ARF-p53 axis Epithelial derived-matrix metalloproteinase (MMP9) exhibits a novel defensive role of tumor suppressor in colitis associated cancer by activating MMP9-Notch1-ARF-p53 axis

14 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Ramireddy BommireddyRamireddy Bommireddy
Ramireddy Bommireddy
SSShannon Stone
Shannon Stone
Noopur BhatnagarNoopur Bhatnagar
Noopur Bhatnagar
PKPratima Kumari
Pratima Kumari
LMLuis E. Munoz
Luis E. Munoz
PSPeriasamy Selvaraj
Periasamy Selvaraj
Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since millions of people are exposed to influenza virus and SARS-CoV-2, it is of great interest to develop a two-in-one vaccine that will be able to protect against infection of both viruses. We have developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 RBD fused to GM-CSF as an adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid vaccine induced a strong antibody response and protected mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice. These results suggest that a hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections.

18 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BPBo Ryoung Park
Bo Ryoung Park
KKKi-Hye Kim
Ki-Hye Kim
TKTatiana Kotomina
Tatiana Kotomina
MKMin-Chul Kim
Min-Chul Kim
YKYoung-Man Kwon
Young-Man Kwon
SKSang-Moo Kang
Sang-Moo Kang
Hemagglutinin (HA)-based current vaccines provide suboptimum cross protection. Influenza A virus contains an ion channel protein M2 conserved extracellular domain (M2e), a target for developing universal vaccines. Here we generated reassortant influenza virus rgH3N2 4xM2e virus (HA and NA from A/Switzerland/9715293/2013/(H3N2)) expressing chimeric 4xM2e-HA fusion proteins with 4xM2e epitopes inserted into the H3 HA N-terminus. Recombinant rgH3N2 4xM2e virus was found to retain equivalent growth kinetics as rgH3N2 in egg substrates. Intranasal single inoculation of mice with live rgH3N2 4xM2e virus was effective in priming the induction of M2e specific IgG antibody responses in mucosal and systemic sites as well as T cell responses. The rgH3N2 4xM2e primed mice were protected against a broad range of different influenza A virus subtypes including H1N1, H3N2, H5N1, H7N9, and H9N2. The findings support a new approach to improve the efficacy of current vaccine platforms by recombinant influenza virus inducing immunity to HA and cross protective M2e antigens.

18 December 2021 in Antiviral Research
Verified
Journal Article
Closed access
Noopur BhatnagarNoopur Bhatnagar
Noopur Bhatnagar
KKKi-Hye Kim
Ki-Hye Kim
JSJeeva Subbiah
Jeeva Subbiah
BPBo Ryoung Park
Bo Ryoung Park
EKEun-Ju Ko
Eun-Ju Ko
SKSang-Moo Kang
Sang-Moo Kang

29 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
KKKi-Hye Kim
Ki-Hye Kim
Noopur BhatnagarNoopur Bhatnagar
Noopur Bhatnagar
JSJEEVA SUBBIAH
JEEVA SUBBIAH
JOJudy Oh
Judy Oh
BPBo Ryoung Park
Bo Ryoung Park
SKSang-Moo Kang
Sang-Moo Kang
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be expanding the pandemic disease across the globe. Although SARS-CoV-2 vaccines were rapidly developed and approved for emergency use of vaccination in humans, supply and production difficulties are slowing down the global vaccination program. The efficacy of many different versions of vaccine candidates and adjuvant effects remain unknown, particularly in the elderly. In this study, we compared the immunogenic properties of SARS-CoV-2 full-length spike (S) ectodomain in young adult and aged mice, S1 with receptor binding domain, and S2 with fusion domain. Full-length S was more immunogenic and effective in inducing IgG antibodies after low dose vaccination, compared to the S1 subunit. Old-aged mice induced SARS-CoV-2 spike-specific IgG antibodies with neutralizing activity after high dose S vaccination. With an increased vaccine dose, S1 was highly effective in inducing neutralizing and receptor-binding inhibiting antibodies, although both S1 and S2 subunit domain vaccines were similarly immunogenic. Adjuvant effects were significant for effective induction of IgG1 and IgG2a isotypes, neutralizing and receptor-binding inhibiting antibodies, and antibody-secreting B cell and interferon-γ secreting T cell immune responses. Results of this study provide information in designing SARS-CoV-2 spike vaccine antigens and effective vaccination in the elderly.